Thiotepa is an alkylating agent used to prevent graft rejection in stem cell transplantation and to treat a variety of malignancies including certain types of adenocarcinoma and superficial bladder carcinomas. N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years.
- Mechanism
- Curator reviewed
The alkyl group is attached to the guanine base of DNA, at the number 7 nitrogen atom of the imidazole ring. They stop tumor growth by crosslinking guanine nucleobases in DNA double-helix strands, directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. These drugs act nonspecifically.
- Primary indication
- ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients.Curator reviewed · 4 structured indications
- Formula / weight
- C6H12N3PS · 189.218 g/mol (avg)
- First approval
- Canada, 2003 · United States, 2001 · European Union, 2021
- Also known as
- N,N′,N′′-tri-1,2-ethanediyl- · Phosphorothioic acid triethylenetriamide · Phosphorothioic triamide, N,N′,N′′-tri-1,2-ethanediyl- · Thiophosphamide · Thiophosphoramide
- Code names
- SH-105 · WR 45312
- Brand names
Resolves to
FOCVUCIESVLUNU-UHFFFAOYSA-NSMILESS=P(N1CC1)(N1CC1)N1CC1What you can answer from here — as of September 23, 2026
Which other approved drugs treat the same conditions as Thiotepa, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account